These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 21216126)

  • 1. Determination of the nateglinide polymorphic purity through DSC.
    Bruni G; Berbenni V; Milanese C; Girella A; Cardini A; Lanfranconi S; Marini A
    J Pharm Biomed Anal; 2011 Apr; 54(5):1196-9. PubMed ID: 21216126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new crystal form of nateglinide.
    Li G; Su GQ; Xu QW; Zhu CQ
    Yao Xue Xue Bao; 2001 Jul; 36(7):532-4. PubMed ID: 12585087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thermodynamic relationships between nateglinide polymorphs.
    Bruni G; Berbenni V; Milanese C; Girella A; Cardini A; Viganò E; Lanfranconi S; Marini A
    J Pharm Biomed Anal; 2009 Dec; 50(5):764-70. PubMed ID: 19570642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compatibility studies of nateglinide with excipients in immediate release tablets.
    Pani NR; Nath LK; Acharya S
    Acta Pharm; 2011 Jun; 61(2):237-47. PubMed ID: 21684850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of crystal polymorphs of nateglinide by DSC].
    Lin KJ; Chen W; You QD
    Yao Xue Xue Bao; 2002 Jan; 37(1):46-9. PubMed ID: 12579899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New solid modifications of nateglinide.
    Bruni G; Berbenni V; Milanese C; Girella A; Cardini A; Lanfranconi S; Marini A
    J Pharm Biomed Anal; 2010 Apr; 51(5):1054-9. PubMed ID: 20022441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A validated stability indicating LC method for Nateglinide.
    Pathare DB; Jadhav AS; Shingare MS
    Drug Dev Ind Pharm; 2007 May; 33(5):551-7. PubMed ID: 17520447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing.
    Maggi L; Bruni G; Maietta M; Canobbio A; Cardini A; Conte U
    Int J Pharm; 2013 Sep; 454(1):562-7. PubMed ID: 23867985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of polymorphic impurity in an enantiotropic polymorph system using differential scanning calorimetry, X-ray powder diffraction and Raman spectroscopy.
    Li Y; Chow PS; Tan RB
    Int J Pharm; 2011 Aug; 415(1-2):110-8. PubMed ID: 21645601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of high-speed differential scanning calorimetry (Hyper-DSC) in the study of pharmaceutical polymorphs.
    McGregor C; Bines E
    Int J Pharm; 2008 Feb; 350(1-2):48-52. PubMed ID: 17890030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced dissolution and bioavailability of Nateglinide by microenvironmental pH-regulated ternary solid dispersion: in-vitro and in-vivo evaluation.
    Wairkar S; Gaud R; Jadhav N
    J Pharm Pharmacol; 2017 Sep; 69(9):1099-1109. PubMed ID: 28590055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating relative stability of polymorphs by generation of configurational free energy phase diagram.
    Upadhyay P; Dantuluri AK; Kumar L; Bansal AK
    J Pharm Sci; 2012 May; 101(5):1843-51. PubMed ID: 22344848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nateglinide quantification in rabbit plasma by HPLC: optimization and application to pharmacokinetic study.
    Sankalia JM; Sankalia MG; Sutariya VB; Mashru RC
    J Pharm Biomed Anal; 2007 May; 44(1):196-204. PubMed ID: 17398055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of the nateglinide polymorphism structure and the drug effect.
    Li G; Chen JY; Lü GL; Xu QW
    Yao Xue Xue Bao; 2005 Oct; 40(10):958-60. PubMed ID: 16408818
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterisation of paracetamol form III with rapid-heating DSC.
    Gaisford S; Buanz AB; Jethwa N
    J Pharm Biomed Anal; 2010 Nov; 53(3):366-70. PubMed ID: 20478676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reevaluation of solubility of tolbutamide and polymorphic transformation from Form I to unknown crystal form.
    Hasegawa G; Komasaka T; Bando R; Yoshihashi Y; Yonemochi E; Fujii K; Uekusa H; Terada K
    Int J Pharm; 2009 Mar; 369(1-2):12-8. PubMed ID: 19026732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential scanning calorimetry (DSC) and temperature-modulated DSC study of three mouthguard materials.
    Meng FH; Schricker SR; Brantley WA; Mendel DA; Rashid RG; Fields HW; Vig KW; Alapati SB
    Dent Mater; 2007 Dec; 23(12):1492-9. PubMed ID: 17412412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.
    Twaites B; Wilton LV; Layton D; Shakir SA
    Acta Diabetol; 2007 Dec; 44(4):233-9. PubMed ID: 17874223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring crystallisation of drugs from fast-dissolving oral films with isothermal calorimetry.
    Gaisford S; Verma A; Saunders M; Royall PG
    Int J Pharm; 2009 Oct; 380(1-2):105-11. PubMed ID: 19596058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sample preparation method on quantification of polymorphs using PXRD.
    Alam S; Patel S; Bansal AK
    Pharm Dev Technol; 2010; 15(5):452-9. PubMed ID: 19842910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.